Literature DB >> 7515445

The management of patients with nonseminomatous germ cell tumors of the testis with serologic disease only after orchiectomy.

B E Davis1, H W Herr, W R Fair, G J Bosl.   

Abstract

Management of patients with nonseminomatous germ cell tumors of the testis who have persistently elevated serum tumor marker levels (alpha-fetoprotein and/or human chorionic gonadotropin) following orchiectomy and no clinical evidence of disease is controversial. We reviewed our experience with 15 such patients at our cancer center between March 1977 and November 1991. Group 1 (11 patients) underwent initial retroperitoneal lymph node dissection and group 2 (4 patients) received primary chemotherapy. All group 1 patients required subsequent chemotherapy for retroperitoneal disease or persistent marker elevation, whereas only 1 of the 4 who received primary chemotherapy required later surgery. We conclude that tumor marker elevation in this setting is usually indicative of systemic tumor, which is best treated primarily by initial chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7515445     DOI: 10.1016/s0022-5347(17)32830-6

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

1.  Three cycles of etoposide and cisplatin chemotherapy in clinical stage IS nonseminomatous testicular cancer.

Authors:  Zaza Mezvrishvili; Laurent Managadze
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

2.  False elevation of human chorionic gonadotropin in a patient with testicular cancer.

Authors:  David J Gallagher; Jamie Riches; Dean F Bajorin
Journal:  Nat Rev Urol       Date:  2010-04       Impact factor: 14.432

Review 3.  Current controversies on the role of retroperitoneal lymphadenectomy for testicular cancer.

Authors:  Roy Mano; Renzo Di Natale; Joel Sheinfeld
Journal:  Urol Oncol       Date:  2018-11-13       Impact factor: 3.498

Review 4.  Current management and management controversies in early- and intermediate-stage of nonseminoma germ cell tumors.

Authors:  Salim K Cheriyan; Marilin Nicholson; Ahmet M Aydin; Mounsif Azizi; Charles C Peyton; Wade J Sexton; Scott M Gilbert
Journal:  Transl Androl Urol       Date:  2020-01

5.  [The role of tumour markers in diagnosis and management of testicular germ cell tumours].

Authors:  S Krege; P Albers; A Heidenreich
Journal:  Urologe A       Date:  2011-03       Impact factor: 0.639

6.  Management of good-risk metastatic nonseminomatous germ cell tumors of the testis: current concepts and controversies.

Authors:  Gautam Jayram; Russell Z Szmulewitz; Scott E Eggener
Journal:  Indian J Urol       Date:  2010 Jan-Mar

7.  Clinical outcomes in patients with stage I non-seminomatous germ cell cancer.

Authors:  Zhao-Jie Lv; Song Wu; Pei Dong; Kai Yao; Yin-Yin He; Yao-Ting Gui; Fang-Jian Zhou; Zhuo-Wei Liu; Zhi-Ming Cai
Journal:  Asian J Androl       Date:  2013-05-20       Impact factor: 3.285

8.  Current management of testicular cancer.

Authors:  Yu Seob Shin; Hyung Jin Kim
Journal:  Korean J Urol       Date:  2013-01-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.